Literature DB >> 8529715

The age at onset of chronic Pseudomonas aeruginosa colonization in cystic fibrosis--prognostic significance.

C Aebi1, R Bracher, S Liechti-Gallati, H Tschäppeler, A Rüdeberg, R Kraemer.   

Abstract

To evaluate the prognostic significance of the age at onset of chronic Pseudomonas aeruginosa colonization (OPCP) with respect to pulmonary disease progression in patients with cystic fibrosis (CF), a retrospective long-term analysis using annual chest radiographs was performed on 54 CF patients. Thirty-seven patients (68%) were chronically colonized before the age of 12 years (group 1), 17 patients (32%) thereafter (group 2). These two groups did not significantly differ in terms of mean duration of follow up (16.2 +/- 5.9 years), sex, CF genotypes, colonization with other respiratory pathogens, supportive medical treatment and death rate during the study period. Chest radiographs were evaluated according to the Chrispin-Norman score, increasing scores representing increasing severity of respiratory disease. In both groups, progression of score means was not accelerated of score means was not accelerated up to 6 years after OCPC (Scores at OCPC set 0; mean score +/- SEM 6 years prior to OCPC -5.6 +/- 2.0; 10 years after OCPC +3.6 +/- 0.7 points). Patients chronically colonized prior to age 12 years (group 1) scored significantly higher between age 2 and 11 years (maximum difference at age 8 years [mean +/- SEM]: 9.4 +/- 0.7 vs. 4.3 +/- 1.3 points; P = 0.002) as compared to group 2. After age 11 years, mean scores were similar in both groups, since in group 2 scores increased rapidly after age 8 years. We conclude that OCPC did not cause an immediate acceleration of CF lung disease judged by serial chest radiographs. Rapid progression in group 2 (OCPC after age 12 years) was independent of OCPC since it occurred earlier. These data indicate that OCPC may be a marker rather than the cause of respiratory disease progression.

Entities:  

Mesh:

Year:  1995        PMID: 8529715     DOI: 10.1007/bf02191510

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  20 in total

1.  A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis.

Authors:  L E GIBSON; R E COOKE
Journal:  Pediatrics       Date:  1959-03       Impact factor: 7.124

2.  Haplotype analysis for CF-linked DNA polymorphisms in Switzerland.

Authors:  S Liechti-Gallati; B U Niederer; V Schneider; M Mächler; M Alkan; N Malik; S Braga; H Moser
Journal:  Clin Genet       Date:  1990-06       Impact factor: 4.438

3.  Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa.

Authors:  E Kerem; M Corey; R Gold; H Levison
Journal:  J Pediatr       Date:  1990-05       Impact factor: 4.406

Review 4.  Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey.

Authors:  N Hoiby
Journal:  Acta Pathol Microbiol Scand Suppl       Date:  1977

5.  Relative underweight in cystic fibrosis and its prognostic value.

Authors:  R Kraemer; A Rüdeberg; B Hadorn; E Rossi
Journal:  Acta Paediatr Scand       Date:  1978-01

6.  Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti-Pseudomonas aeruginosa antibody levels and pulmonary function.

Authors:  G B Winnie; R G Cowan
Journal:  Pediatr Pulmonol       Date:  1991

7.  Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients.

Authors:  S S Pedersen; T Jensen; N Høiby; C Koch; E W Flensborg
Journal:  Acta Paediatr Scand       Date:  1987-11

8.  IgG subclass antibody responses to alginate from Pseudomonas aeruginosa in patients with cystic fibrosis and chronic P. aeruginosa infection.

Authors:  T Pressler; S S Pedersen; F Espersen; N Høiby; C Koch
Journal:  Pediatr Pulmonol       Date:  1992-09

9.  Quantitative differences in goblet cells in the tracheal epithelium of male and female rats.

Authors:  M Hayashi; G L Huber
Journal:  Am Rev Respir Dis       Date:  1977-04

10.  Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years.

Authors:  V L Hudson; C L Wielinski; W E Regelmann
Journal:  J Pediatr       Date:  1993-06       Impact factor: 4.406

View more
  9 in total

Review 1.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

2.  Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung disease.

Authors:  Jessica E Pittman; Elizabeth H Calloway; Michelle Kiser; John Yeatts; Stephanie D Davis; Mitchell L Drumm; Michael S Schechter; Margaret W Leigh; Mary Emond; Annelies Van Rie; Michael R Knowles
Journal:  Pediatr Pulmonol       Date:  2010-12-30

Review 3.  Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  Bridget Stuart; Jenny H Lin; Peter J Mogayzel
Journal:  Paediatr Respir Rev       Date:  2010-06-16       Impact factor: 2.726

Review 4.  Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature.

Authors:  Federico Marchetti; Luisella Giglio; Manila Candusso; Dino Faraguna; Baroukh M Assael
Journal:  Eur J Clin Pharmacol       Date:  2004-03-05       Impact factor: 2.953

5.  Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.

Authors:  Drucy Borowitz; Karen A Robinson; Margaret Rosenfeld; Stephanie D Davis; Kathryn A Sabadosa; Stephanie L Spear; Suzanne H Michel; Richard B Parad; Terry B White; Philip M Farrell; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

6.  Proteomic identification of OprL as a seromarker for initial diagnosis of Pseudomonas aeruginosa infection of patients with cystic fibrosis.

Authors:  Aparna R Rao; Anita Laxova; Philip M Farrell; Joseph T Barbieri
Journal:  J Clin Microbiol       Date:  2009-06-24       Impact factor: 5.948

7.  Uncovering symptom progression history from disease registry data with application to young cystic fibrosis patients.

Authors:  Jun Yan; Yu Cheng; Jason P Fine; Huichuan J Lai
Journal:  Biometrics       Date:  2009-06-12       Impact factor: 2.571

8.  Onset of persistent pseudomonas aeruginosa infection in children with cystic fibrosis with interval censored data.

Authors:  Wenjie Wang; Ming-Hui Chen; Sy Han Chiou; Hui-Chuan Lai; Xiaojing Wang; Jun Yan; Zhumin Zhang
Journal:  BMC Med Res Methodol       Date:  2016-09-17       Impact factor: 4.615

9.  Reduced neutrophil elastase inhibitor elafin and elevated transforming growth factor-β1 are linked to inflammatory response in sputum of cystic fibrosis patients with Pseudomonas aeruginosa.

Authors:  Jan C Thomassen; Tobias Trojan; Maxine Walz; Christina Vohlen; Gregor Fink; Ernst Rietschel; Miguel A Alejandre Alcazar; Silke van Koningsbruggen-Rietschel
Journal:  ERJ Open Res       Date:  2021-07-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.